Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2002 Mar;72(3):310–314. doi: 10.1136/jnnp.72.3.310

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

O Lopez 1, J Becker 1, S Wisniewski 1, J Saxton 1, D Kaufer 1, S DeKosky 1
PMCID: PMC1737770  PMID: 11861686

Abstract

Objective: To describe the effect of cholinesterase inhibitors (CEIs) on the natural course of Alzheimer's disease (AD).

Methods: The short and long term effects of CEIs were evaluated in 135 patients with probable Alzheimer's disease relative to 135 patients who were never exposed to CEIs matched by age, education, duration of the symptoms, and cognitive status. We measured 1 year change in cognitive and functional performance, and the likelihood of arriving at each of four end points: (1) mini mental state examination (MMSE) of 9 or lower, (2) Blessed dementia rating scale for activities of daily living of 12 or higher, (3) nursing home admission, and (4) death, over an average 3 years of observation (36.7 (SD 21.5) months).

Results: Patients on CEIs were better cognitively and functionally after 1 year compared with those patients who never used CEIs. A proportional hazard analysis with CEI use as a time dependent covariate showed that the use of CEIs decreased the risk of nursing home admission. There was no association, however, between use of CEIs and time to cognitive and functional end points, or to death.

Conclusions: This observational study showed that there was an initial cognitive and functional benefit from the use of CEIs in Alzheimer's disease, which waned as the disease progressed. However, the results suggest that there is a long term beneficial effect of the use of CEIs, as indicated by the delay in adsmission to nursing homes.

Full Text

The Full Text of this article is available as a PDF (108.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blessed G., Tomlinson B. E., Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968 Jul;114(512):797–811. doi: 10.1192/bjp.114.512.797. [DOI] [PubMed] [Google Scholar]
  2. Doody R. S., Geldmacher D. S., Gordon B., Perdomo C. A., Pratt R. D., Donepezil Study Group Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001 Mar;58(3):427–433. doi: 10.1001/archneur.58.3.427. [DOI] [PubMed] [Google Scholar]
  3. Farlow M., Gracon S. I., Hershey L. A., Lewis K. W., Sadowsky C. H., Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA. 1992 Nov 11;268(18):2523–2529. [PubMed] [Google Scholar]
  4. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  5. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56–62. doi: 10.1136/jnnp.23.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hachinski V. C., Iliff L. D., Zilhka E., Du Boulay G. H., McAllister V. L., Marshall J., Russell R. W., Symon L. Cerebral blood flow in dementia. Arch Neurol. 1975 Sep;32(9):632–637. doi: 10.1001/archneur.1975.00490510088009. [DOI] [PubMed] [Google Scholar]
  7. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  8. Hughes C. P., Berg L., Danziger W. L., Coben L. A., Martin R. L. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982 Jun;140:566–572. doi: 10.1192/bjp.140.6.566. [DOI] [PubMed] [Google Scholar]
  9. Knopman D., Schneider L., Davis K., Talwalker S., Smith F., Hoover T., Gracon S. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology. 1996 Jul;47(1):166–177. doi: 10.1212/wnl.47.1.166. [DOI] [PubMed] [Google Scholar]
  10. Lopez O. L., Becker J. T., Klunk W., Saxton J., Hamilton R. L., Kaufer D. I., Sweet R. A., Cidis Meltzer C., Wisniewski S., Kamboh M. I. Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II. Neurology. 2000 Dec 26;55(12):1863–1869. doi: 10.1212/wnl.55.12.1863. [DOI] [PubMed] [Google Scholar]
  11. Lopez O. L., Becker J. T., Klunk W., Saxton J., Hamilton R. L., Kaufer D. I., Sweet R. A., Cidis Meltzer C., Wisniewski S., Kamboh M. I. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology. 2000 Dec 26;55(12):1854–1862. doi: 10.1212/wnl.55.12.1854. [DOI] [PubMed] [Google Scholar]
  12. Lopez O. L., Wisnieski S. R., Becker J. T., Boller F., DeKosky S. T. Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol. 1997 Aug;54(8):969–975. doi: 10.1001/archneur.1997.00550200033007. [DOI] [PubMed] [Google Scholar]
  13. Lopez O. L., Wisniewski S. R., Becker J. T., Boller F., DeKosky S. T. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999 Oct;56(10):1266–1272. doi: 10.1001/archneur.56.10.1266. [DOI] [PubMed] [Google Scholar]
  14. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  15. McShane R., Keene J., Gedling K., Fairburn C., Jacoby R., Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ. 1997 Jan 25;314(7076):266–270. doi: 10.1136/bmj.314.7076.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mohs R. C., Doody R. S., Morris J. C., Ieni J. R., Rogers S. L., Perdomo C. A., Pratt R. D., "312" Study Group A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001 Aug 14;57(3):481–488. doi: 10.1212/wnl.57.3.481. [DOI] [PubMed] [Google Scholar]
  17. Qizilbash N., Whitehead A., Higgins J., Wilcock G., Schneider L., Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA. 1998 Nov 25;280(20):1777–1782. doi: 10.1001/jama.280.20.1777. [DOI] [PubMed] [Google Scholar]
  18. Raskind M. A., Peskind E. R., Wessel T., Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000 Jun 27;54(12):2261–2268. doi: 10.1212/wnl.54.12.2261. [DOI] [PubMed] [Google Scholar]
  19. Rogers S. L., Doody R. S., Mohs R. C., Friedhoff L. T. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11;158(9):1021–1031. doi: 10.1001/archinte.158.9.1021. [DOI] [PubMed] [Google Scholar]
  20. Rogers S. L., Doody R. S., Pratt R. D., Ieni J. R. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000 May;10(3):195–203. doi: 10.1016/s0924-977x(00)00067-5. [DOI] [PubMed] [Google Scholar]
  21. Rogers S. L., Farlow M. R., Doody R. S., Mohs R., Friedhoff L. T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan;50(1):136–145. doi: 10.1212/wnl.50.1.136. [DOI] [PubMed] [Google Scholar]
  22. Rogers S. L., Friedhoff L. T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol. 1998 Feb;8(1):67–75. doi: 10.1016/s0924-977x(97)00079-5. [DOI] [PubMed] [Google Scholar]
  23. Rogers S. L., Friedhoff L. T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia. 1996 Nov-Dec;7(6):293–303. doi: 10.1159/000106895. [DOI] [PubMed] [Google Scholar]
  24. Rösler M., Anand R., Cicin-Sain A., Gauthier S., Agid Y., Dal-Bianco P., Stähelin H. B., Hartman R., Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633–638. doi: 10.1136/bmj.318.7184.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Salmon D. P., Thal L. J., Butters N., Heindel W. C. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology. 1990 Aug;40(8):1225–1230. doi: 10.1212/wnl.40.8.1225. [DOI] [PubMed] [Google Scholar]
  26. Tariot P. N., Mack J. L., Patterson M. B., Edland S. D., Weiner M. F., Fillenbaum G., Blazina L., Teri L., Rubin E., Mortimer J. A. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry. 1995 Sep;152(9):1349–1357. doi: 10.1176/ajp.152.9.1349. [DOI] [PubMed] [Google Scholar]
  27. Tariot P. N., Solomon P. R., Morris J. C., Kershaw P., Lilienfeld S., Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000 Jun 27;54(12):2269–2276. doi: 10.1212/wnl.54.12.2269. [DOI] [PubMed] [Google Scholar]
  28. Thal L. J., Ferguson J. M., Mintzer J., Raskin A., Targum S. D. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 1999 Apr 12;52(6):1146–1152. doi: 10.1212/wnl.52.6.1146. [DOI] [PubMed] [Google Scholar]
  29. Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wimo A., Wetterholm A. L., Zhang R., Haglund A., Subbiah P. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001 Aug 14;57(3):489–495. doi: 10.1212/wnl.57.3.489. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES